Bills Address Women's Health and Cancer Issues

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

WASHINGTON--Cancer ranked high among a package of seven Senate bills introduced by Sen. Olympia Snowe (R-Maine), all of them intended to address women's health issues.

WASHINGTON--Cancer ranked high among a package of seven Senate billsintroduced by Sen. Olympia Snowe (R-Maine), all of them intended to addresswomen's health issues.

The "Consumer Involvement in Breast Cancer Act" would requirethe National Institutes of Health to include breast cancer advocates inits decision-making on breast cancer research.

Under the "Breast Cancer Screening Act of 1997," the NationalCancer Institute would have to reissue the mammog-raphy guidelines forwomen in their 40s that it dropped in 1993.

The "Breast Cancer Research Extension Act of 1997" would increasethe funding authorization for breast cancer research in fiscal year 1998,which begins Oct. 1, by $59 million, to a total of $590 million.

In addition, Sen. Snowe's "One-Stop Shopping Information Service"bill, co-introduced by Sen. Diane Feinstein (D-Calif), would require thesecretary of Health and Human Services to establish a database of all publicand private clinical trials in the United States that patients with life-threateningillnesses could access via a toll-free telephone number.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content